News | November 04, 2024
Biocon reports Q2 FY25 net loss at Rs. 16 Cr
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
This office will be the central hub for all operations related to companies ethical pharmaceutical business
Stable profits, low leverage to keep credit profiles comfortable
Chobhe brings over 30 years of extensive experience in quality and regulatory management within the pharmaceutical industry
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
Combined entity is better positioned to compete in increasingly competitive generics industry
Subscribe To Our Newsletter & Stay Updated
